Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 489 across all filing types
Latest filing 2022-08-30 AGM Information
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Extraordinary General Meeting in Oncopeptides AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Extraordinary General Meeting in Oncopeptides AB (publ)" and details the notice, agenda, procedures (advance voting), and proposed resolutions for this meeting. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (or Extraordinary General Meeting, as this is a notice for one). Although it is a notice, the content is the core material for the meeting itself, making AGM-R the most specific fit over a general RPA or RNS.
2022-08-30 English
Extra bolagsstämma i Oncopeptides AB (publ)
AGM Information Classification · 98% confidence The document is titled "Extra bolagsstämma i Oncopeptides AB (publ)" (Extra General Meeting in Oncopeptides AB (publ)) and details the process for shareholders to participate via advance voting (poströstning) on a specific date (September 23, 2022). It outlines the agenda, voting requirements, and shareholder rights concerning this meeting. This content directly relates to the formal proceedings and materials associated with a General Meeting, specifically an Extraordinary General Meeting (EGM), which falls under the scope of AGM Information (AGM-R), as it covers meeting procedures and proposals.
2022-08-30 Swedish
European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma
Regulatory Filings Classification · 100% confidence The document is explicitly titled as a "Press release" dated August 18, 2022, announcing that the "European Commission has granted Pepaxti®... marketing authorization." It details the approval, the basis for the approval (Phase 2/3 studies), and future commercialization plans. This type of announcement, which is a formal communication of a significant corporate event (regulatory approval) outside of the standard periodic financial reports (like 10-K or IR), is best classified as a general Regulatory Filing or announcement. Since it is not a transcript (CT), an earnings release (ER), a management discussion (MDA), or a specific shareholder vote result (DVA), the most appropriate general category for a significant, non-periodic regulatory milestone announcement is Regulatory Filings (RNS). It is not a Report Publication Announcement (RPA) because it is the primary announcement of the event itself, not just an announcement that a report is available.
2022-08-18 English
EU-kommissionen godkänner Oncopeptides Pepaxti för behandling av patienter med trippelklassrefraktärt multipelt myelom
Regulatory Filings Classification · 95% confidence The document is a press release dated August 18, 2022, announcing that the European Commission has granted marketing authorization for Oncopeptides' drug Pepaxti for treating triple-class refractory multiple myeloma. This type of announcement, detailing a significant regulatory decision (drug approval) and its immediate implications (launch plans), is characteristic of a corporate news release regarding a major business event. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a formal Audit Report (AR). Since it is a specific announcement of a major corporate event (regulatory approval) that impacts the business and product pipeline, it fits best under the general category of Regulatory Filings (RNS) as a primary announcement, or potentially a Capital/Financing Update (CAP) if the approval was tied to financing, but the core content is the regulatory news itself. Given the options, RNS serves as the best general category for significant, non-standardized regulatory news announcements that aren't explicitly covered by other codes like ER or DIV. However, since this is a major product approval announcement, which is a key driver for investor interest, and it is structured as a formal press release, it is a significant regulatory event announcement. Since there is no specific code for 'Drug Approval Announcement', RNS (Regulatory Filings) is the most appropriate fallback for a major regulatory milestone announcement that is not a standard periodic report.
2022-08-18 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Q2 2022, containing comprehensive financial statements (income statement, cash flow, balance sheet data), management commentary on business trends, and operational updates. It is not an announcement of a report, but the report itself, containing substantive financial data for the period ending June 30, 2022. Q2 2022
2022-08-11 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT – Q2, 2022' and contains comprehensive financial statements, including income statements, cash flow data, and management commentary for the period ending June 30, 2022. It provides detailed financial performance metrics and operational updates, fitting the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, as it contains the full financial data and analysis. Q2 2022
2022-08-11 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.